|
|
|
|
| LEADER |
03856nmm a2200361 u 4500 |
| 001 |
EB000365881 |
| 003 |
EBX01000000000000000218933 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9781597454704
|
| 100 |
1 |
|
|a Bronchud, Miguel H.
|e [editor]
|
| 245 |
0 |
0 |
|a Principles of Molecular Oncology
|h Elektronische Ressource
|c edited by Miguel H. Bronchud, MaryAnn Foote, Giuseppe Giaccone, Olufunmilayo I. Olopade, Paul Workman
|
| 250 |
|
|
|a 3rd ed. 2008
|
| 260 |
|
|
|a Totowa, NJ
|b Humana
|c 2008, 2008
|
| 300 |
|
|
|a XX, 420 p. 85 illus., 21 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Selecting the Right Targets for Cancer Therapy -- Clinical Importance of Prognostic Factors -- Genetic Markers in Sporadic Tumors -- Genetic Markers in Breast Tumors with Hereditary Predisposition -- Circulating Tumor Markers -- Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways -- Gene Expression Arrays for Pathway Analysis in Cancer Research -- Signaling Pathways in Cancer -- Estrogen Receptor Pathways and Breast Cancer -- Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics -- Angiogenesis Switch Pathways -- Apoptosis Pathways and New Anticancer Agents -- Genomic Instability, DNA Repair Pathways and Cancer -- Epigenomics and Cancer -- Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well? -- Aurora Kinases: A New Target for Anticancer Drug Development -- Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways -- Suicide Gene Therapy -- Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs -- A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?
|
| 653 |
|
|
|a Hematology
|
| 653 |
|
|
|a Medicine / Research
|
| 653 |
|
|
|a Biology / Research
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Biomedical Research
|
| 653 |
|
|
|a Cancer Biology
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Foote, MaryAnn
|e [editor]
|
| 700 |
1 |
|
|a Giaccone, Giuseppe
|e [editor]
|
| 700 |
1 |
|
|a Olopade, Olufunmilayo I.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 028 |
5 |
0 |
|a 10.1007/978-1-59745-470-4
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-59745-470-4?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616,994
|
| 520 |
|
|
|a Drawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, pharmacogenomics, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules. The first edition of this book (Humana Press, 2000) was also the first comprehensive presentation of the concept of cancer as a "disease process" involving key regulatory pathways. The second edition (2004) reaffirmed this dynamic concept, incorporating more recent evidence, and introducing such new topics of special interest as the combination of molecular diagnostics-expression profiling of genes and proteins- with developmental therapeutics, and the "binary state" concept (active/inactive) that seeks more relevant targets within the global molecular matrix of a given cancer. Comprehensive and intellectually stimulating, POMO III not only clearly elucidates the fundamentals of this dramatically advancing field, but also interprets the vast and often complex molecular data available. It fills a much neglected gap between "information" and "knowledge," and holds out the hope of new anticancer strategies that will reduce the process of carcinogenesis, cancer cell proliferation and significantly reduce metastasis
|